The Greek Preclinical Arbitrage

For Series A/B biotechs under pressure to extend their capital runway, the "Greek Arbitrage" represents a rational capital allocation decision rather than a compromise on quality. ALTP offers a 40–50% cost advantage over US and Swiss hubs by utilizing the specialized labor market in Athens, where a deep pool of Western-trained, English-speaking scientists operates under a single EU-compliant quality framework.

We provide a seamless transition from discovery to IND, integrating translational swine surgical models with in-house rodent DMPK and LC-MS/MS bioanalytical services. Operating under EU Directive 2010/63/EU, all documentation is produced to meet both EMA and FDA dossier standards, ensuring that your capital-efficient research maintains the highest Western regulatory alignment.